Showing results (1831-1840 of 3,159) with videos related to
Sort By:
Pageof 316
Neuro-Oncology|January 12, 2023
EANO guideline on rational molecular testing of gliomas, glioneuronal, and neuronal tumors in adults for targeted therapy selectionDavid Capper, Guido Reifenberger, Pim J French, et al.Neuro-Oncology|January 14, 2023
Targeting the IL4 receptor with MDNA55 in patients with recurrent glioblastoma: Results of a phase IIb trialJohn H Sampson, Achal Singh Achrol, Manish K Aghi, et al.Neuro-Oncology|December 26, 2022
Mitotic count is prognostic in IDH mutant astrocytoma without homozygous deletion of CDKN2A/B. Results of consensus panel review of EORTC trial 26053 (CATNON) and EORTC trial 22033-26033Johan M Kros, Elisabeth Rushing, Aimé L Uwimana, et al.Neuro-Oncology|July 8, 2022
Quantitative proteomic landscapes of primary and recurrent glioblastoma reveal a protumorigeneic role for FBXO2-dependent glioma-microenvironment interactionsMarcel Buehler, Xiao Yi, Weigang Ge, et al.Neuro-Oncology|June 29, 2021
The 2021 WHO Classification of Tumors of the Central Nervous System: a summaryDavid N Louis, Arie Perry, Pieter Wesseling, et al.Neuro-Oncology|July 16, 2021
Neurosurgical resection for locally recurrent brain metastasisAlexander F C Hulsbergen, Abdullah M Abunimer, Fidelia Ida, et al.Neuro-Oncology|July 2, 2021
Newly established patient-derived organoid model of intracranial meningiomaShintaro Yamazaki, Fumiharu Ohka, Masaki Hirano, et al.Neuro-Oncology|May 13, 2022
Limited surgery and conformal photon radiation therapy for pediatric craniopharyngioma: long-term results from the RT1 protocolDrucilla Y Edmonston, Shengjie Wu, Yimei Li, et al.Neuro-Oncology|July 23, 2021
Selective blood-brain barrier permeabilization of brain metastases by a type 1 receptor-selective tumor necrosis factor muteinMario F Munoz Pinto, Sandra J Campbell, Christina Simoglou Karali, et al.Neuro-Oncology|October 21, 2003
Does brain tumor histology influence cognitive function?Anne E Kayl, Christina A MeyersPageof 316